1241 / 1851
Time after treatment (months)
0 6 12 18 24 30 36 42 48 54 60
Loco-regional control (%)
0
20
40
60
80
100
27%
DAHANCA Database
Stage 3-4 Larynx and Pharynx
5 fx/wk
5 fx/wk + NIM
44%
62%
83%
6 fx/wk + NIM
6 fx/wk + NIM + cis-P
645 pts
255 pts
713 pts
411 pts
Standard 1985
Standard 2007
Benefit of Hypoxic
Modification
Benefit of
Accelerated
Fractionation
Benefit of Chemo-
Radiotherapy
DAHANCA strategy: progression through clinical trials
Adapted from Overgard and Lassen 2015